Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemiaMark A. Dawson, Tony Kouzarides, Rab K. Prinjha et al.|Nature|2011Cited by 1.5k
A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumoursGabriel Mak, Hendrik‐Tobias Arkenau, Li Yan et al.|British Journal of Cancer|2019Cited by 103
A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098Nicholas F. Brown, Paul Mulholland, Matthew Williams et al.|Neuro-Oncology|2018Cited by 83
Inhibition of BET Recruitment to Chromatin As An Effective Treatment for MLL-Fusion LeukaemiaMark A. Dawson, Brian J.P. Huntly, Rab K. Prinjha et al.|Blood|2011Cited by 38
A phase Ib dose-escalation study of GSK2256098 (FAKi) plus trametinib (MEKi) in patients with selected advanced solid tumors.Hendrik‐Tobias Arkenau, Li Yan, Anas Gazzah et al.|Journal of Clinical Oncology|2015Cited by 7